Akero Therapeutics Inc. (NASDAQ:AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced that ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

A large-scale, multi-center international study published in the European Heart Journal has shown that EchoGo® Amyloidosis, an AI-powered tool developed by Ultromics, significantly improves the ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

Amyloidosis is a rare and possibly life-threatening disease affecting an estimated 4,000 people per year in the US. If left untreated, the disease can cause severe organ damage, so early detection is ...

AL amyloidosis can be found in newly diagnosed 2 patients with MM or can develop later in their disease course, 16 which bodes poorly for these patients. 17 Historically, the converse—that is, ...